➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Dow
Medtronic
Express Scripts
Mallinckrodt

Last Updated: October 24, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Clindamycin Phosphate In Dextrose 5%

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00160394 Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris Completed GlaxoSmithKline Phase 4 2004-12-01 Comparing the efficacy and safety of a gel formulation containing a combination of clindamycin phosphate (equivalent to 1% clindamycin) and benzoyl peroxide (5%) once daily with a gel containing 0.1% adapalene once daily in the treatment of acne vulgaris of mild to moderate severity.
NCT00160394 Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris Completed Stiefel, a GSK Company Phase 4 2004-12-01 Comparing the efficacy and safety of a gel formulation containing a combination of clindamycin phosphate (equivalent to 1% clindamycin) and benzoyl peroxide (5%) once daily with a gel containing 0.1% adapalene once daily in the treatment of acne vulgaris of mild to moderate severity.
NCT00219570 Dalacin-T Gel Post Approval Study Completed Acronet Phase 4 2005-01-01 To investigate, in a comparison vs. Acuatim cream (nadifloxacin cream), the efficacy and safety of Dalacin T Gel (clindamycin phosphate gel) as a therapeutic medication for acne vulgaris in acne vulgaris patients, including children ages 13 and up, in order to clarify the clinical positioning of Dalacin T Gel.
NCT00219570 Dalacin-T Gel Post Approval Study Completed Bellsystem24 , Inc. Phase 4 2005-01-01 To investigate, in a comparison vs. Acuatim cream (nadifloxacin cream), the efficacy and safety of Dalacin T Gel (clindamycin phosphate gel) as a therapeutic medication for acne vulgaris in acne vulgaris patients, including children ages 13 and up, in order to clarify the clinical positioning of Dalacin T Gel.
NCT00219570 Dalacin-T Gel Post Approval Study Completed Mitsubishi Kagaku Bio-Clinical Laboratories, inc Phase 4 2005-01-01 To investigate, in a comparison vs. Acuatim cream (nadifloxacin cream), the efficacy and safety of Dalacin T Gel (clindamycin phosphate gel) as a therapeutic medication for acne vulgaris in acne vulgaris patients, including children ages 13 and up, in order to clarify the clinical positioning of Dalacin T Gel.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Clindamycin Phosphate In Dextrose 5%

Condition Name

Condition Name for Clindamycin Phosphate In Dextrose 5%
Intervention Trials
Acne Vulgaris 18
Acne 2
MILD TO SEVERE ACNE VULGARIS 1
Vulvovaginal Inflammation (Objective): Absent, Mild, Moderate, or Severe. 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Clindamycin Phosphate In Dextrose 5%
Intervention Trials
Acne Vulgaris 20
Vaginosis, Bacterial 2
Vaginal Diseases 2
Vaginal Discharge 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Clindamycin Phosphate In Dextrose 5%

Trials by Country

Trials by Country for Clindamycin Phosphate In Dextrose 5%
Location Trials
United States 31
India 13
China 10
Poland 1
Spain 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Clindamycin Phosphate In Dextrose 5%
Location Trials
New York 5
Pennsylvania 4
California 3
Florida 3
North Carolina 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Clindamycin Phosphate In Dextrose 5%

Clinical Trial Phase

Clinical Trial Phase for Clindamycin Phosphate In Dextrose 5%
Clinical Trial Phase Trials
Phase 4 10
Phase 3 8
Phase 2/Phase 3 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Clindamycin Phosphate In Dextrose 5%
Clinical Trial Phase Trials
Completed 18
Recruiting 6
Unknown status 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Clindamycin Phosphate In Dextrose 5%

Sponsor Name

Sponsor Name for Clindamycin Phosphate In Dextrose 5%
Sponsor Trials
GlaxoSmithKline 6
Stiefel, a GSK Company 4
Zeichner, Joshua, M.D. 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Clindamycin Phosphate In Dextrose 5%
Sponsor Trials
Industry 30
Other 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Moodys
Express Scripts
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.